Brennan FR, Morton LD, Spindeldreher S, Kiessling A, Allenspach R, Hey A, et al. Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies. MAbs. 2010;2(3):233–55. https://doi.org/10.4161/mabs.2.3.11782.

Article  PubMed Central  PubMed  Google Scholar 

Zahavi D, Weiner L. Monoclonal antibodies in cancer therapy. Antibodies (Basel). 2020. https://doi.org/10.3390/antib9030034.

Article  PubMed Central  PubMed  Google Scholar 

Lucchi R, Bentanachs J, Oller-Salvia B. The masking game: design of activatable antibodies and mimetics for selective therapeutics and cell control. ACS Cent Sci. 2021;7(5):724–38. https://doi.org/10.1021/acscentsci.0c01448.

Article  CAS  PubMed Central  PubMed  Google Scholar 

Joest EF, Tampe R. Design principles for engineering light-controlled antibodies. Trends Biotechnol. 2023;41(12):1501–17. https://doi.org/10.1016/j.tibtech.2023.06.006.

Article  CAS  PubMed  Google Scholar 

Adhikari P, Li G, Go M, Mandikian D, Rafidi H, Ng C, et al. On demand bioorthogonal switching of an antibody-conjugated SPECT probe to a cytotoxic payload: from imaging to therapy. J Am Chem Soc. 2024;146(28):19088–100. https://doi.org/10.1021/jacs.4c03529.

Article  CAS  PubMed  Google Scholar 

Song SH, Ghosh T, You DG, Joo H, Lee J, Lee J, et al. Functionally masked antibody to uncouple immune-related toxicities in checkpoint blockade cancer therapy. ACS Nano. 2023;17(11):10065–77. https://doi.org/10.1021/acsnano.2c12532.

Article  CAS  PubMed  Google Scholar 

Chen IJ, Chuang CH, Hsieh YC, Lu YC, Lin WW, Huang CC, et al. Selective antibody activation through protease-activated pro-antibodies that mask binding sites with inhibitory domains. Sci Rep. 2017;7(1):11587. https://doi.org/10.1038/s41598-017-11886-7.

Article  CAS  PubMed Central  PubMed  Google Scholar 

Lin WW, Lu YC, Chuang CH, Cheng TL. Ab locks for improving the selectivity and safety of antibody drugs. J Biomed Sci. 2020;27(1):76. https://doi.org/10.1186/s12929-020-00652-z.

Article  CAS  PubMed Central  PubMed  Google Scholar 

Donaldson JM, Kari C, Fragoso RC, Rodeck U, Williams JC. Design and development of masked therapeutic antibodies to limit off-target effects: application to anti-EGFR antibodies. Cancer Biol Ther. 2009;8(22):2147–52. https://doi.org/10.4161/cbt.8.22.9765.

Article  CAS  PubMed  Google Scholar 

Autio KA, Boni V, Humphrey RW, Naing A. Probody therapeutics: an emerging class of therapies designed to enhance on-target effects with reduced off-tumor toxicity for use in immuno-oncology. Clin Cancer Res. 2020;26(5):984–9. https://doi.org/10.1158/1078-0432.CCR-19-1457.

Article  CAS  PubMed  Google Scholar 

Desnoyers LR, Vasiljeva O, Richardson JH, Yang A, Menendez EE, Liang TW, et al. Tumor-specific activation of an EGFR-targeting probody enhances therapeutic index. Sci Transl Med. 2013;5(207):207ra144. https://doi.org/10.1126/scitranslmed.3006682.

Article  CAS  PubMed  Google Scholar 

Lucchi R, Lucana MC, Escobar-Rosales M, Diaz-Perlas C, Oller-Salvia B. Site-specific antibody masking enables conditional activation with different stimuli. N Biotechnol. 2023;78:76–83. https://doi.org/10.1016/j.nbt.2023.10.004.

Article  CAS  PubMed  Google Scholar 

Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–23. https://doi.org/10.1056/NEJMoa1003466.

Article  CAS  PubMed Central  PubMed  Google Scholar 

Tao J, Dhanjee HH, Gribble MW Jr, Kottisch V, Rodriguez J, Brown JS, et al. Site-specific antibody prodrugs via s-arylation: a bioconjugation approach toward masked tyrosine analogues. J Am Chem Soc. 2024;146(29):20080–5. https://doi.org/10.1021/jacs.4c04035.

Article  CAS  PubMed  Google Scholar 

Vinogradova EV, Zhang C, Spokoyny AM, Pentelute BL, Buchwald SL. Organometallic palladium reagents for cysteine bioconjugation. Nature. 2015;526(7575):687–91. https://doi.org/10.1038/nature15739.

Article  CAS  PubMed Central  PubMed  Google Scholar 

Rather GM, Lin SY, Lin H, Banach-Petrosky W, Hirshfield KM, Lin CY, et al. Activated matriptase as a target to treat breast cancer with a drug conjugate. Oncotarget. 2018;9(40):25983–92. https://doi.org/10.18632/oncotarget.25414.

Article  PubMed Central  PubMed  Google Scholar 

Maloney DG, Grillo-Lopez AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin’s lymphoma. Blood. 1997;90(6):2188–95.

Article  CAS  PubMed  Google Scholar 

Baselga J. Phase I and II clinical trials of trastuzumab. Ann Oncol. 2001;12(Suppl 1):S49–55. https://doi.org/10.1093/annonc/12.suppl_1.s49.

Article  PubMed  Google Scholar 

Trang VH, Zhang X, Yumul RC, Zeng W, Stone IJ, Wo SW, et al. A coiled-coil masking domain for selective activation of therapeutic antibodies. Nat Biotechnol. 2019;37(7):761–5. https://doi.org/10.1038/s41587-019-0135-x.

Article  CAS  PubMed  Google Scholar 

Lu YC, Chuang CH, Chuang KH, Chen IJ, Huang BC, Lee WH, et al. Specific activation of pro-Infliximab enhances selectivity and safety of rheumatoid arthritis therapy. PLoS Biol. 2019;17(6):e3000286. https://doi.org/10.1371/journal.pbio.3000286.

Article  CAS  PubMed Central  PubMed  Google Scholar 

Lee WH, Shen YR, Huang BC, Ho KW, Chen CK, Wu HH, et al. Protease-activated anti-Lewis Y antibody enhances selectivity and safety of glycan-targeting cancer therapy. Int J Biol Macromol. 2025;309(Pt 4):143176. https://doi.org/10.1016/j.ijbiomac.2025.143176.

Article  CAS  PubMed  Google Scholar 

Lin WW, Lu YC, Huang BC, Chuang CH, Cheng YA, Chen IJ, et al. Selective activation of pro-anti-IL-1beta antibody enhances specificity for autoinflammatory disorder therapy. Sci Rep. 2021;11(1):14846. https://doi.org/10.1038/s41598-021-94298-y.

Article  CAS  PubMed Central  PubMed  Google Scholar 

Liao TY, Liu YL, Chen CY, Wu BT, Liu ES, Hong ST, et al. Development of a tumor-region-selective activation monoclonal antibody targeting the 4–1BB receptor for enhanced therapeutic efficacy and safety. Int J Biol Macromol. 2025;305(Pt 2):141003. https://doi.org/10.1016/j.ijbiomac.2025.141003.

Article  CAS  PubMed  Google Scholar 

Erster O, Thomas JM, Hamzah J, Jabaiah AM, Getz JA, Schoep TD, et al. Site-specific targeting of antibody activity in vivo mediated by disease-associated proteases. J Control Release. 2012;161(3):804–12. https://doi.org/10.1016/j.jconrel.2012.05.035.

Article  CAS  PubMed Central  PubMed  Google Scholar 

Sanborn RE, Hamid O, de Vries EG, Ott PA, Garcia-Corbacho J, Boni V, et al. CX-072 (pacmilimab), a probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding study. J Immunother Cancer. 2021. https://doi.org/10.1136/jitc-2021-002446.

Article  PubMed Central  PubMed  Google Scholar 

Thomas JS, Selfridge JE, Albany C, Taylor MH, Mehmi I, Kwatra V, Hu-Lieskovan S, de Souza PL, Llorin-Sangalang JD, Aysola K, Hamid O. Phase 1 study of BA3071, an anti–CTLA-4 conditionally active biologic, in combination with nivolumab in advanced solid tumors. In: ASCO Annual Meeting; May 31–June 4, 2024: American Society of Clinical Oncology; 2024. p. Abstract 2602.

Amini AP, Kirkpatrick JD, Wang CS, Jaeger AM, Su S, Naranjo S, et al. Multiscale profiling of protease activity in cancer. Nat Commun. 2022;13(1):5745. https://doi.org/10.1038/s41467-022-32988-5.

Article  CAS  PubMed Central  PubMed